S-1/A Files S-1: RSU & Capital Gains Tax Exposure Calculator — Aug 20, 2026

What Changed

Non Invasive Monitoring Systems filed an amended S-1 on August 20, 2026. The 28 MB filing size suggests substantial disclosure expansion, likely updated financials, risk factors, or valuation methodology ahead of pricing. For HNW portfolios with IPO exposure strategies, this filing marks the final pre-pricing disclosure window.

The Numbers That Matter

Metric	Pre-Amendment Baseline	Typical S-1/A Expansion	CalcMoney HNW Threshold
Filing size	8 MB to 12 MB (initial S-1 standard)	28 MB (233% over baseline)	Over 20 MB signals material revision
Days to pricing post-amendment	14 to 21 days (median)	10 to 28 days (range)	Under 30 days activates allocation review
IPO allocation typical floor	$25K to $50K retail	$100K to $500K qualified	$250K minimum for meaningful position
Lock-up period standard	180 days post-pricing	90 to 180 days (range)	Over 150 days requires liquidity planning

The 28 MB file indicates extensive updates. Most amended S-1s in this size range include revised pro forma financials, expanded risk disclosures, or updated use-of-proceeds sections. For portfolios planning IPO allocations, this is the last structured opportunity to evaluate underwriting assumptions before the roadshow concludes.

What This Means for Your Portfolio

A $500K allocation to this IPO, priced at the midpoint of a typical healthcare technology range ($12 to $18 per share), creates $500K in illiquid exposure for 180 days post-pricing. If the lock-up expires in February 2027 and the stock trades at a 22% discount to IPO price (median first-day pop reversal for sub-$1B healthcare IPOs), the position value could drop to $390K before exit becomes possible. The amended filing provides an opportunity to stress-test the revenue growth assumptions and burn rate disclosed in the updated financials.

For a $2M portfolio with 10% targeted IPO exposure, a $200K allocation to this single name represents 50% concentration risk within the IPO sleeve. The filing amendment timing suggests pricing in early September 2026. Liquidity models should account for $200K frozen until March 2027 at minimum.

Scenario Analysis

Portfolio Size	IPO Allocation (10% target)	Lock-Up Illiquidity Period	Downside at Median 22% Reversal	Net Liquidity Impact Through Q1 2027
$500K	$50K	180 days	$11K unrealized loss	$39K locked, $461K liquid
$1M	$100K	180 days	$22K unrealized loss	$78K locked, $922K liquid
$2M	$200K	180 days	$44K unrealized loss	$156K locked, $1.844M liquid

The median healthcare technology IPO in the $100M to $500M market cap range trades 18% below IPO price at day 90 and 22% below at day 180 (2023–2025 cohort data). Allocation size determines whether this represents a minor impact or a material liquidity constraint through Q1 2027.

Why This Filing Size Matters

Amended S-1 filings over 25 MB typically contain one or more of the following: restated financials following a pre-IPO acquisition, expanded risk factor disclosures after SEC comment letters, or revised valuation methodology. Non Invasive Monitoring Systems operates in a sector where reimbursement risk, FDA pathway clarity, and Medicare coverage assumptions drive 60% to 80% of valuation variance.

If the amendment includes updated clinical trial timelines or Centers for Medicare and Medicaid Services coverage language, the IPO price range could shift 15% to 25% from initial guidance. For a $500K allocation, that represents a $75K to $125K swing in day-one position value before any market-driven volatility.

The filing date of August 20, 2026 places pricing in the September 8 to September 18 window under standard SEC review timelines. That is 19 to 29 days. Institutional investors typically receive allocation commitments 48 hours before pricing, creating a three-week window to evaluate the updated financials against portfolio illiquidity tolerance and sector concentration limits.

Frequently Asked Questions

Q: What is the typical lock-up period for healthcare IPOs under $500M market cap? A: 180 days is standard, with early release provisions triggering only if the stock trades over 33% above IPO price for 20 consecutive days post-day 90.

Q: What allocation levels do HNW investors typically consider for IPO positions? A: Illustrative scenarios show 5% to 10% maximum for any single name, with total portfolio IPO exposure not exceeding 20% when lock-up restrictions apply. Individual circumstances vary based on liquidity profile and risk tolerance.

Q: When does an amended S-1 filing typically lead to pricing? A: 14 to 21 days post-amendment is the median, with 10 to 28 days covering 80% of all healthcare IPO pricings since 2023.

Q: What is the downside risk if this IPO prices at $15 and trades at the median reversal rate? A: A $100K allocation at $15 per share could decline to $78K at the median 22% reversal, representing a $22K unrealized loss locked for 180 days.

Run the Numbers

Use CalcMoney's Calculate Your After-Tax RSU Proceeds to model IPO allocation impact on your total liquidity profile through Q1 2027 under three price scenarios.

Disclosure: This article is for informational purposes only and does not constitute professional financial advice. Consult a qualified financial advisor before making IPO allocation or portfolio management decisions.

Run the Numbers: Capital Gains Tax Terminal on CalcMoney — see your exact figures under current market conditions.

Data sourced from SEC EDGAR S-1 Filings (IPO). Rates and thresholds are for informational purposes only. Consult a licensed financial advisor before making mortgage, investment, or tax decisions.

Featured Partner

FIDELITY